Concepedia

The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants

Sylvie Berthou, Daniel M. Aebersold, Laura S. Schmidt, Deborah Stroka, Christine Heigl, Bruno Streit, Denise Stalder, Guenther Gruber, Congxin Liang, Anthony R. Howlett,

Oncogene · 2004 · 179 citations · 22 references

DOI

Concepts

References

22

Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors

George D. Demetri, Margaret von Mehren, Charles D. Blanke et al. · New England Journal of Medicine · 2002 · 4.4K citations · Full text

, , +14

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

Brian Druker, Shu Tamura, Elisabeth Buchdunger et al. · Nature Medicine · 1996 · 3.7K citations

, , +13

Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia

Hagop Kantarjian, Charles L. Sawyers, Andreas Hochhaus et al. · New England Journal of Medicine · 2002 · 2K citations · Full text

, , +14

Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas

Laura S. Schmidt, Fuh-Mei Duh, Fan Chen et al. · Nature Genetics · 1997 · 1.5K citations

, , +17

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

Allan T. van Oosterom, Ian Judson, Jaap Verweij et al. · The Lancet · 2001 · 1.3K citations

, , +12